Badger Meter, Inc. (NYSE: BMI), a manufacturer of flow measurement and control technologies, is likely to benefit from a healthy overall outlook for the North American metering market as well as its latest product offerings, according to Canaccord Genuity.
Analyst Chip Moore upgraded shares of Badger Meter from Sell to Hold and increased the price target from $40 to $44.
The downside risk for Badger Meter is lower due to a more favorable domestic municipal market and continued momentum for oil, gas and industrial applications, Moore said in the upgrade note. Favorable weather in the second quarter is another a positive, the analyst said.
While Badger's technology and overall market positioning is likable, the stock's valuation is at the higher end of historical ranges, giving it a balanced risk-reward profile, Moore said.
Canaccord projects that price increases will help offset the impact of rising commodity costs. A lower tax rate would give Badger additional competitive flexibility, Moore said.
Several other initiatives are expected to incrementally benefit profitability in late 2018, the analyst said.
Badger's second-quarter gross margin is likely to contract 120 basis points year-over-year to 38.2 percent, but increase 320 basis points sequentially as the price of copper approaches multiyear highs, according to Canaccord.
Badger's Q2 report is scheduled for July 18 after the close. Canaccord forecast revenue and earnings per share of $112 million and 41 cents, respectively, compared to consensus estimates that call for revenue of $111.9 million and EPS of 40 cents.
The Price Action
Badger Meter shares have lost about 5.1 percent year-to-date.
A.O. Smith Should Outperform Peers, Goldman Sachs Says In Upgrade
Domestic Construction, Chinese Market Share Are Driving A.O. Smith's Growth, Analyst Says In Bullish Initiation
Latest Ratings for BMI
|Jun 2018||Canaccord Genuity||Upgrades||Sell||Hold|
|Apr 2018||Stifel Nicolaus||Maintains||Hold||Hold|
View More Analyst Ratings for BMI
View the Latest Analyst Ratings
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug
- The Cloud Rains Opportunity For Alibaba; Wells Fargo Projects 21% Upside In Shares
- Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.